Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.

Orlando KA, Nguyen V, Raab JR, Walhart T, Weissman BE.

Expert Rev Anticancer Ther. 2019 May;19(5):375-391. doi: 10.1080/14737140.2019.1605905. Epub 2019 May 13.

PMID:
30986130
2.

NRF2 Activation in Cancer: From DNA to Protein.

Cloer EW, Goldfarb D, Schrank TP, Weissman BE, Major MB.

Cancer Res. 2019 Mar 1;79(5):889-898. doi: 10.1158/0008-5472.CAN-18-2723. Epub 2019 Feb 13. Review.

PMID:
30760522
3.

Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG.

Mol Cancer Ther. 2018 Dec;17(12):2767-2779. doi: 10.1158/1535-7163.MCT-18-0348. Epub 2018 Sep 19.

PMID:
30232145
4.

High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice.

Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, Rathmell WK, Weissman BE.

Am J Pathol. 2018 Jul;188(7):1510-1516. doi: 10.1016/j.ajpath.2018.03.010. Epub 2018 Apr 22.

5.

Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.

Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM.

Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. doi: 10.1158/1078-0432.CCR-17-1928. Epub 2018 Feb 9.

6.

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.

J Pathol. 2017 Jul;242(3):371-383. doi: 10.1002/path.4912. Epub 2017 Jun 2.

PMID:
28444909
7.

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.

Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG.

J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.

8.

Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.

Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG, Xu J, Kuwahara Y, Allen SJ, Erdreich-Epstein A, Weissman BE, Orr BA, Eberhart CG, Biegel JA, Raabe EH.

Oncotarget. 2015 Feb 20;6(5):3165-77.

9.

The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity.

Kaur H, Hütt-Cabezas M, Weingart MF, Xu J, Kuwahara Y, Erdreich-Epstein A, Weissman BE, Eberhart CG, Raabe EH.

J Neuropathol Exp Neurol. 2015 Feb;74(2):177-85. doi: 10.1097/NEN.0000000000000161.

10.

SWI/SNF chromatin remodeling complexes and cancer.

Biegel JA, Busse TM, Weissman BE.

Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):350-66. doi: 10.1002/ajmg.c.31410. Epub 2014 Aug 28. Review.

11.

SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.

Wei D, Goldfarb D, Song S, Cannon C, Yan F, Sakellariou-Thompson D, Emanuele M, Major MB, Weissman BE, Kuwahara Y.

Mol Cancer Res. 2014 Nov;12(11):1574-85. doi: 10.1158/1541-7786.MCR-14-0005. Epub 2014 Jul 9.

12.

Gene silencing associated with SWI/SNF complex loss during NSCLC development.

Song S, Walter V, Karaca M, Li Y, Bartlett CS, Smiraglia DJ, Serber D, Sproul CD, Plass C, Zhang J, Hayes DN, Zheng Y, Weissman BE.

Mol Cancer Res. 2014 Apr;12(4):560-70. doi: 10.1158/1541-7786.MCR-13-0427. Epub 2014 Jan 20.

13.

SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.

Kuwahara Y, Wei D, Durand J, Weissman BE.

Mol Cancer Res. 2013 Mar;11(3):251-60. doi: 10.1158/1541-7786.MCR-12-0390. Epub 2013 Jan 30.

14.

Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.

Kuwahara Y, Mora-Blanco EL, Banine F, Rogers AB, Fletcher C, Sherman LS, Roberts CW, Weissman BE.

Int J Cancer. 2013 Jun 15;132(12):2767-77. doi: 10.1002/ijc.27976. Epub 2012 Dec 27.

15.

Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene.

DelBove J, Rosson G, Strobeck M, Chen J, Archer TK, Wang W, Knudsen ES, Weissman BE.

Epigenetics. 2011 Dec;6(12):1444-53. doi: 10.4161/epi.6.12.18492.

16.

BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest.

Bartlett C, Orvis TJ, Rosson GS, Weissman BE.

J Cell Physiol. 2011 Aug;226(8):1989-97. doi: 10.1002/jcp.22533.

17.

BRG1 co-localizes with DNA replication factors and is required for efficient replication fork progression.

Cohen SM, Chastain PD 2nd, Rosson GB, Groh BS, Weissman BE, Kaufman DG, Bultman SJ.

Nucleic Acids Res. 2010 Nov;38(20):6906-19. doi: 10.1093/nar/gkq559. Epub 2010 Jun 22.

18.

Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism.

Kuwahara Y, Charboneau A, Knudsen ES, Weissman BE.

Cancer Res. 2010 Mar 1;70(5):1854-65. doi: 10.1158/0008-5472.CAN-09-1922. Epub 2010 Feb 23.

19.

Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.

DelBove J, Kuwahara Y, Mora-Blanco EL, Godfrey V, Funkhouser WK, Fletcher CD, Van Dyke T, Roberts CW, Weissman BE.

Mol Carcinog. 2009 Dec;48(12):1139-48. doi: 10.1002/mc.20568.

20.

Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation.

Chai J, Lu X, Godfrey V, Fletcher C, Roberts CW, Van Dyke T, Weissman BE.

Cancer Res. 2007 Apr 1;67(7):3002-9.

21.

Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.

De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, Coussens LM, Cohen MB.

Cancer Biol Ther. 2006 Dec;5(12):1588-99. Epub 2006 Dec 6. No abstract available.

PMID:
17224636
22.
23.

BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton.

Rosson GB, Bartlett C, Reed W, Weissman BE.

J Cell Physiol. 2005 Nov;205(2):286-94.

PMID:
15887247
24.

SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.

Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS.

Cancer Res. 2005 May 1;65(9):3542-7.

25.

The expression of the SWI/SNF ATPase subunits BRG1 and BRM in normal human tissues.

Reisman DN, Sciarrotta J, Bouldin TW, Weissman BE, Funkhouser WK.

Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):66-74.

PMID:
15722796
26.

The Ews/Fli-1 fusion gene changes the status of p53 in neuroblastoma tumor cell lines.

Rorie CJ, Weissman BE.

Cancer Res. 2004 Oct 15;64(20):7288-95.

27.

The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors.

Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE.

Cancer Res. 2004 Feb 15;64(4):1266-77.

28.

Chromosome 18 suppresses prostate cancer metastases.

Padalecki SS, Weldon KS, Reveles XT, Buller CL, Grubbs B, Cui Y, Yin JJ, Hall DC, Hummer BT, Weissman BE, Dallas M, Guise TA, Leach RJ, Johnson-Pais TL.

Urol Oncol. 2003 Sep-Oct;21(5):366-73.

PMID:
14670546
29.

Hybrid capture of putative tumor suppressor genes.

Betz BL, Weissman BE.

Methods Mol Biol. 2003;222:365-73. No abstract available.

PMID:
12710698
30.

Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE.

Cancer Res. 2003 Feb 1;63(3):560-6.

32.

Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.

Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE.

Oncogene. 2002 Aug 8;21(34):5193-203.

33.

Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.

Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W Jr, Murchardt C, Yaniv M, Sherman LS, Knudsen ES, Weissman BE.

Oncogene. 2002 Feb 14;21(8):1196-207.

34.

Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling.

Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES.

J Biol Chem. 2002 Feb 15;277(7):4782-9. Epub 2001 Nov 21.

35.

Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.

Xu XL, Wu LC, Du F, Davis A, Peyton M, Tomizawa Y, Maitra A, Tomlinson G, Gazdar AF, Weissman BE, Bowcock AM, Baer R, Minna JD.

Cancer Res. 2001 Nov 1;61(21):7943-9.

36.

Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.

Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, Delattre O.

Oncogene. 2001 May 31;20(25):3258-65.

37.

Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.

Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE.

J Cell Physiol. 2001 Jan;186(1):136-45.

PMID:
11147808
38.

The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression.

Strobeck MW, DeCristofaro MF, Banine F, Weissman BE, Sherman LS, Knudsen ES.

J Biol Chem. 2001 Mar 23;276(12):9273-8. Epub 2000 Dec 6.

39.

Altered response of a human squamous cell carcinoma cell line to 1, 25-dihydroxyvitamin D(3) after transfer of a normal chromosome 11.

Merrihew RV, Cruickshank RD, Conway K, Weissman BE.

Exp Cell Res. 2000 Aug 25;259(1):191-203.

PMID:
10942591
40.

BRG-1 is required for RB-mediated cell cycle arrest.

Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, Knudsen ES.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7748-53.

41.

A human melanoma metastasis-suppressor locus maps to 6q16.3-q23.

Miele ME, Jewett MD, Goldberg SF, Hyatt DL, Morelli C, Gualandi F, Rimessi P, Hicks DJ, Weissman BE, Barbanti-Brodano G, Welch DR.

Int J Cancer. 2000 May 15;86(4):524-8.

42.

Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.

DeCristofaro MF, Betz BL, Wang W, Weissman BE.

Oncogene. 1999 Dec 9;18(52):7559-65.

43.

WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.

Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS.

EMBO J. 1999 Jul 15;18(14):3990-4003.

44.

Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids.

Isfort RJ, Cody DB, Lovell GJ, Gioeli D, Weissman BE, Doersen CJ.

Mol Carcinog. 1999 May;25(1):30-41.

PMID:
10331742
45.

Induction of rat WT1 gene expression correlates with human chromosome 11p11.2-p12-mediated suppression of tumorigenicity in rat liver epithelial tumor cell lines.

Coleman WB, Ricketts SL, Borchert KM, Presnell SC, Esch GL, McCullough KD, Weissman BE, Smith GJ, Grisham JW.

Int J Oncol. 1999 May;14(5):957-63.

PMID:
10200348
46.
47.

Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1).

West A, Vojta PJ, Welch DR, Weissman BE.

Genomics. 1998 Nov 15;54(1):145-8.

PMID:
9806840
48.

Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines.

Isaacs JS, Hardman R, Carman TA, Barrett JC, Weissman BE.

Cell Growth Differ. 1998 Jul;9(7):545-55.

49.

Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain.

Cooper PR, Smilinich NJ, Day CD, Nowak NJ, Reid LH, Pearsall RS, Reece M, Prawitt D, Landers J, Housman DE, Winterpacht A, Zabel BU, Pelletier J, Weissman BE, Shows TB, Higgins MJ.

Genomics. 1998 Apr 1;49(1):38-51.

PMID:
9570947
50.

KAI1, a putative marker for metastatic potential in human breast cancer.

Yang X, Welch DR, Phillips KK, Weissman BE, Wei LL.

Cancer Lett. 1997 Nov 11;119(2):149-55.

PMID:
9570365

Supplemental Content

Loading ...
Support Center